NMRA · Neumora Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $38.60M | - | $40.52M | $38.72M | $52.15M | - | $60.63M | $32.77M | $45.76M | - |
| SG&A | $14.27M | - | $12.18M | $15.32M | $18.79M | - | $16.02M | $9.29M | $14.32M | - |
| Total Operating Expenses | $52.86M | - | $57.70M | $54.04M | $70.94M | - | $76.65M | $42.06M | $60.07M | - |
| D&A | $8.0K | - | - | - | $157.0K | - | - | - | $158.0K | - |
| Operating Income | ($52.86M) | - | ($57.70M) | ($54.04M) | ($70.94M) | - | ($76.65M) | ($42.06M) | ($60.07M) | - |
| Interest Expense | $1.44M | - | $0 | - | - | - | - | - | - | - |
| Income Tax | $30.0K | - | $0 | $25.0K | $105.0K | - | $53.0K | $125.0K | - | - |
| Net Income | ($53.46M) | - | ($56.76M) | ($52.73M) | ($67.99M) | - | ($72.55M) | ($58.70M) | ($53.72M) | - |
| EPS - Basic | ($0.30) | - | ($0.35) | ($0.33) | ($0.42) | - | ($0.45) | ($1.28) | ($0.34) | - |
| EPS - Diluted | ($0.30) | - | ($0.35) | ($0.33) | ($0.42) | - | ($0.45) | ($1.28) | ($0.34) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147.07M | $182.53M | $129.07M | $124.52M | $126.86M | $142.15M | $275.71M | $150.68M | $210.87M | $374.04M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.06M | $3.38M | $549.0K | $644.0K | $1.05M | $3.31M | $6.11M | $1.08M | $1.49M | $337.0K |
| Current Assets | $153.43M | $190.54M | $177.08M | $222.91M | $254.87M | $314.06M | $348.61M | $398.32M | $442.79M | $478.28M |
| Total Assets | $153.88M | $191.05M | $177.83M | $223.82M | $256.75M | $316.97M | $352.54M | $404.47M | $450.21M | $496.19M |
| Current Liabilities | $30.11M | $32.45M | $25.84M | $21.16M | $28.38M | $29.89M | $31.74M | $23.13M | $24.61M | $25.11M |
| Long-term Debt | $52.96M | $54.53M | $19.56M | $19.45M | - | - | - | - | - | - |
| Total Liabilities | $83.20M | $87.18M | $45.67M | $40.95M | $28.38M | $29.91M | $31.80M | $23.21M | $25.67M | $27.12M |
| Stockholders' Equity | $70.68M | $103.87M | $132.16M | $182.88M | $228.36M | $287.06M | $320.74M | $381.26M | $424.54M | $469.08M |
| Retained Earnings | ($1.24B) | ($1.18B) | ($1.12B) | ($1.07B) | ($1.02B) | ($947.22M) | ($888.40M) | ($815.86M) | ($757.15M) | ($703.43M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($46.40M) | - | - | - | ($59.45M) | - | - | - | ($42.95M) | - |
| Investing Cash Flow | $71.0K | - | - | - | $44.16M | - | - | - | ($150.00M) | - |
| Financing Cash Flow | $10.88M | - | - | - | $0 | - | - | - | $1.84M | - |
| CapEx | - | - | - | - | - | - | - | - | $36.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($42.99M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.80 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -34.7% | - | -31.9% | -23.6% | -26.5% | - | -20.6% | -14.5% | -11.9% | - |
| Return on equity | -75.6% | - | -42.9% | -28.8% | -29.8% | - | -22.6% | -15.4% | -12.7% | - |
| Return on invested capital | -33.8% | - | -30.0% | -21.1% | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.09 | 5.87 | 6.85 | 10.54 | 8.98 | 10.51 | 10.98 | 17.22 | 17.99 | 19.05 |
| Quick ratio | 5.09 | 5.87 | 6.85 | 10.54 | 8.98 | 10.51 | 10.98 | 17.22 | 17.99 | 19.05 |
| Cash ratio | 4.88 | 5.62 | 4.99 | 5.89 | 4.47 | 4.76 | 8.69 | 6.52 | 8.57 | 14.90 |
| Leverage | ||||||||||
| Debt / Equity | 0.75 | 0.52 | 0.15 | 0.11 | - | - | - | - | - | - |
| Debt / Assets | 0.34 | 0.29 | 0.11 | 0.09 | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -36.8x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.18 | 1.84 | 1.35 | 1.22 | 1.12 | 1.10 | 1.10 | 1.06 | 1.06 | 1.06 |
| Liabilities / Assets | 0.54 | 0.46 | 0.26 | 0.18 | 0.11 | 0.09 | 0.09 | 0.06 | 0.06 | 0.05 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 5.0x | - | 2.2x | 0.6x | 0.7x | - | 6.6x | 4.1x | 5.1x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 25.5% | - | 24.7% | -28.5% | -18.1% | - | -150.5% | - | - | - |
| Net income growth (YoY) | 21.4% | - | 21.8% | 10.2% | -26.6% | - | -147.2% | - | - | - |
| EPS growth (YoY) | 28.6% | - | 22.2% | 74.2% | -23.5% | - | 60.5% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -69.0% | -63.8% | -58.8% | -52.0% | -46.2% | -38.8% | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Neumora Therapeutics against the 5 most active filers in the same SIC group.